We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




Multi-Disease POC Breathalyzer Sniffs Out Infections and Monitors Patients on Ventilator

By HospiMedica International staff writers
Posted on 19 Jan 2023
Print article
The BREATHGUARD portable MICRO-GC medical device used to detect various biomarkers (Photo courtesy of Blu Biotech)
The BREATHGUARD portable MICRO-GC medical device used to detect various biomarkers (Photo courtesy of Blu Biotech)

A novel diagnostic testing device uses a patient's breath to diagnose various forms of cancer, COVID-19 and related variants, acute respiratory distress syndrome (ARDS), sepsis, and other acute and chronic inflammatory diseases.

Blu Biotech Inc. (Albuquerque, NM, USA) has entered into a patent license agreement with University of Michigan (U-M, Ann Arbor, MI, USA) to develop and commercialize a Micro Gas Chromatography Photoionization Detector (Micro-GC-PID) for use in diagnostic testing. The commercial device will combine high-performance breath analysis with point-of-care utilization for the diagnosis and monitoring of multiple diseases. The device separates >100 volatile chemical compounds in a breath in 10 minutes with a sub-ppb (parts-per-billion), thanks to the micro-scale components such as the microfluidic detector.

Device readings are encrypted and sent to Blu Biotech’s cloud platform where they are analyzed using the company’s proprietary algorithm. The algorithm has been developed based on machine learning and AI to analyze breath patterns revealing diseases and human health conditions. The results are finally relayed back to the device. The Micro GC device is suitable for use in hospitals and at the point-of-care to provide timely information about disease and health conditions. It can be placed at the patient’s bedside to analyze their breath every 30 minutes, similar to an electrocardiogram (ECG) that analyzes the heart condition each second. In clinical trials, the technology has demonstrated the ability to diagnose COVID-19 as well as distinguish between COVID-19 variants. The technology has also shown promise in diagnosing and monitoring of ARDS, which is the severest form of lung injury affecting over 200,000 patients a year.

"We are incredibly excited to have the opportunity to work with the University of Michigan, one of the world's leading research institutions. Together we are going to reduce cancer mortality by early and accurate cancer screening and improve the care of the critically ill and injured. Blu Biotech's expertise in biomarker development, together with University of Michigan's patented hardware, data science and clinical expertise provides for the first time a realistic point of care commercial breath test," said Robert Tavzel, Chief Executive Officer. "At Blu Biotech we continue to expand and develop breath biomarkers. Someday soon we will be able to target many other cancers, autoimmune disease, infectious disease, and even neurologic and heart diseases with the potential to save lives by early detection."

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
12-Channel ECG
CM1200B
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Fiberoptic Laryngoscope Set
Satin

Print article

Channels

Critical Care

view channel
Image: Researchers have made significant advances in ingestible microbiome sampling pill technology (Photo courtesy of Tufts University)

Ingestible Microbiome Sampling Pill to Help Diagnose Wide Range of Health Conditions

The healthy human gut is home to more than 1,000 species of bacteria, most of which play a beneficial role in digestion and protecting against disease. When the natural balance of these microbes is disrupted,... Read more

Surgical Techniques

view channel
Image: New studies suggest benefit of total robotic metabolic and bariatric surgery over conventional laparoscopy (Photo courtesy of 123RF)

Total Robotic Metabolic and Bariatric Surgery Proves More Beneficial than Conventional Laparoscopy

According to the U.S. Centers for Disease Control and Prevention (CDC), 42.4% of Americans are affected by obesity. Research indicates that obesity can compromise the immune system, trigger chronic inflammation,... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.